Product Data Sheet

Thalidomide-4-O-C8-NH2 hydrochloride

 $\begin{array}{lll} \textbf{Cat. No.:} & \text{HY-133485B} \\ \textbf{CAS No.:} & 2636798\text{-}38\text{-}2 \\ \textbf{Molecular Formula:} & C_{21}\text{H}_{28}\text{ClN}_{3}\text{O}_{5} \\ \end{array}$

Molecular Weight: 437.92

Target: E3 Ligase Ligand-Linker Conjugates; Apoptosis; Autophagy

Pathway: PROTAC; Apoptosis; Autophagy

Storage: -20°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

BIOLOGICAL ACTIVITY

Description	Thalidomide-4-O-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology ^[1] .
IC ₅₀ & Target	Cereblon
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA